| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3405702 | Journal of Global Antimicrobial Resistance | 2015 | 5 Pages |
•Daptomycin demonstrated sustained activity against MRSA and VRE from Europe and the USA.•More than 99.9% of contemporary clinical strains were susceptible to daptomycin.•Daptomycin was more potent compared with vancomycin and linezolid against MRSA.•Daptomycin activity was not influenced by oxacillin resistance among S. aureus.•Daptomycin activity was not influenced by vancomycin resistance among enterococci.
This study evaluated daptomycin activity trends among meticillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) over a 5-year period (2009–2013). Consecutive, unique patient isolates of clinical significance were collected in 67 European (EU) (17 nations) and 145 US medical centres and were susceptibility tested in a central reference laboratory against daptomycin and various comparators by CLSI broth microdilution methods. MIC results were interpreted according to EUCAST and CLSI breakpoint criteria (2014). A total of (EU/USA) 14 245/22 967 S. aureus (26.3/49.8% MRSA), 3043/2848 Enterococcus faecalis (1.6/3.5% vancomycin-resistant) and 1827/1537 Enterococcus faecium (29.5/77.7% vancomycin-resistant) were evaluated. Isolates were mainly from complicated skin and skin-structure infections (40%) and bacteraemia (32%). The highest MRSA rates were found in Portugal (66.3%), Russia (52.2%) and the USA (49.8%), whereas the highest rates of vancomycin-resistant E. faecium (VREFM) were observed in the USA (77.7%), Poland (63.1%) and Ireland (54.5%). VREFM and vancomycin-resistant E. faecalis (VREF) were observed in 15 and 8 EU nations, respectively. Daptomycin susceptibility rates were (EU/USA) 99.94/99.97%, 100.0/99.7% and 100.0/99.96% for S. aureus, E. faecium and E. faecalis, respectively. Daptomycin was very active against MRSA (MIC50/90, 0.25/0.5 mg/L in Europe and USA), VREF (MIC50/90 of 0.5/1 mg/L and 1/2 mg/L in Europe and USA, respectively) and VREFM (MIC50/90, 2/2 mg/L in Europe and USA). Among MRSA, only 6/6 (0.19/0.05%) daptomycin-non-susceptible isolates were observed in Europe (six cities in four countries)/USA (six states), with no increasing trend over the study period. Only two daptomycin-non-susceptible VRE were identified, both E. faecium from the USA.
